12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Other News

Forest Laboratories, Glenmark cardiovascular news

Forest and Glenmark settled a March 2012 patent suit claiming Glenmark's ANDA for a generic version of hypertension drug Bystolic nebivolol infringes Forest's U.S. Patent No. 6,545,040. The patent covers methods of treating hypertension with Bystolic and expires in December 2021. Under the settlement, Glenmark will receive a license...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >